The safety and efficacy of oral anticoagulants with dual versus single antiplatelet therapy in patients after percutaneous coronary intervention
A meta-analysis

Jie Chen, MD, Li-Yu Wang, MD, Chao Deng, MD, Xing-Hua Jiang, MD, Tu-Gang Chen, MD, PhD

Abstract

Background: A growing number of patients require oral anticoagulant (OAC) after undergoing percutaneous coronary intervention (PCI) with stent implantation due to the development of atrial fibrillation, but the optimal antithrombotic regimen remains controversial in these patients.

Methods: We systematically searched PUBMED, EMBASE, and CENTRAL from inception until September 2016 for randomized controlled trials or cohort studies that evaluated the comparative effects of TT versus DT. Relative risks (RRs) with 95% confidence intervals (95% CIs) were pooled by a random-effects model or a fixed-effects model.

Results: Twelve studies with a total of 30,823 patients were included in this analysis, including 6134 in the TT group and 24,689 in the DT group. No significant differences were found between the TT group and the DT group regarding major adverse cardiovascular events (MACE) (RR = 0.89, 95% CI: 0.58–1.17; I² = 87.3%), stroke (RR = 1.08, 95% CI: 0.56–2.07; I² = 65.6%), all-cause mortality (RR = 0.90, 95% CI: 0.54–1.51; I² = 79.1%), or stent thrombosis (RR = 0.71, 95% CI: 0.41–1.24; I² = 12.7%), and lower rates were observed for myocardial infarction (RR = 0.59, 95% CI: 0.50–0.70; I² = 31.1%) and major bleeding with TT (RR = 0.86, 95% CI: 0.74–0.99; I² = 24.3%). Meanwhile, we also found that compared with TT, OAC with clopidogrel treatment shows equal efficacy and safety outcomes.

Conclusion: In patients on OAC undergoing PCI with stent implantation, compared with DT, TT shows equal effectiveness in terms of MACE, stroke, all-cause mortality, and stent thrombosis and lower risks of myocardial infarction and major bleeding. However, similar efficacy and safety outcomes were observed between the TT group and the OAC along with clopidogrel group.

Abbreviations: ACS = acute coronary syndrome, CI = confidence interval, DAPT = dual antiplatelet therapy, DT = dual therapy, MACE = major adverse cardiovascular events, MI = myocardial infarction, PCI = percutaneous coronary intervention, RR = relative risk, TT = triple therapy.

Keywords: atrial fibrillation, dual therapy, percutaneous coronary intervention, triple therapy

1. Introduction

In patients with atrial fibrillation, mechanical heart valves, and other venous thromboembolisms, long-term oral anticoagulation (OAC) is essential for the prevention of systemic thromboembolic events.[1] Dual antiplatelet therapy (DAPT) is the basic treatment for patients with myocardial infarction (MI) or acute coronary syndrome (ACS).[2] In fact, 20% to 30% of patients with atrial fibrillation also have ischemic heart disease and require percutaneous coronary intervention (PCI) with stent implantation.[3] Triple therapy (TT; warfarin, aspirin, and clopidogrel) was recommended as the optimal antithrombotic regimen in patients on OAC undergoing PCI with stent implantation. Although TT is more effective in reducing cardiovascular events and stroke, an increasing risk of major bleeding is evident compared with DAPT.[4–7] Therefore, the optimal antithrombotic therapy for these patients remains controversial. Currently, some specialists recommend that dual therapy (DT; OAC with single antiplatelet) can replace TT for similar efficacy outcomes and without the additional risk of bleeding. Therefore, some studies[8–11] and several meta-analyses[6,12,13] have been performed to evaluate the safety and efficacy of TT compared with DT, but the results are inconsistent. A previous meta-analysis showed data selection and methodological biases and 2 new...
studies have since been published.[114,115] Therefore, we performed an updated systematic review and meta-analysis to generate the largest analysis comparing the benefits and risks between TT and DT in patients on OAC undergoing coronary stenting.

2. Methods

2.1. Search strategy

Our review and meta-analysis strictly followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.[116] A systematic search was performed on PubMed, Embase, and CENTRAL (the Cochrane Central Register of Controlled Trials) with no language limitations and the included studies should be published as original literature in peer-reviewed scientific journals. In addition, the references from relevant articles were manually searched for potential studies using combinations of various keywords for the search strategy, including “triple therapy,” “dual therapy,” “oral anticoagulation with antiplatelet therapy,” “percutaneous coronary intervention,” “stent,” and “atrial fibrillation.” Ultimately, 12 studies were included, and our search was updated in September 2016. All analyses were based on previous published studies. Therefore, no ethical approval or patient consent is required.

2.2. Inclusion and exclusion criteria

The inclusion criteria were as follows: OAC with DAPT versus single antiplatelet therapy; direct comparisons between TT and DT; outcomes of interest are reported (see below); and randomized controlled trials (RCTs) or cohort studies with follow-ups ≥6 months. The exclusion criteria were as follows: nonhuman studies; no report of any main outcomes; and duplicate studies or reviews.

2.3. Data extraction and quality assessment

Data extraction was carried out by 2 reviewers independently, and a special standardized form was used to record the following data: study name, publication date, country of study, study design, baseline demographics, and follow-up. The authors of the articles were contacted if the original data were not included in the publication. Controversy was resolved by consensus. The efficacy endpoints included major adverse cardiovascular events (MACE), ischemic stroke, MI, all-cause mortality, and stent thrombosis. Major bleeding was used as a safety endpoint. We used the outcome definitions from the original articles because the meanings of each outcome were slightly different in all included studies. The quality of the included studies was evaluated by 2 reviewers using the Cochrane risk-of-bias tool and the Newcastle-Ottawa assessment tool.[117] Studies were considered low-quality if 2 or more quality assessment items were identified as high or unclear risk of bias.

2.4. Statistical analysis

The pooled effects of the interventions were calculated using relative risk (RR) with 95% confidence intervals (95% CIs). The heterogeneity across the trials was assessed with the Q test and the I² statistic, with \( P < .1 \) and/or \( I^2 > 50\% \), indicating statistically significant heterogeneity. When heterogeneity was present, the randomized-effects model was used. Otherwise, the Mantel–Haenszel fixed-effects model was used. In cases of statistical heterogeneity, sensitivity analyses were carried out by eliminating 1 study at a time to evaluate the influence of each study on the results and the robustness of the results.[118] A subgroup analysis was performed according to the follow-up periods: short-term follow-up (<1 year) and long-term follow-up (≥1 year). The publication bias was tested by a funnel plot and Egger test (\( P \) for significant asymmetry <.1). All data analyses were conducted using Stata 12.0 (Stata Corporation LP, College Station, TX).

3. Results

3.1. Eligible studies and patient characteristics

As shown in Fig. 1, a total of 107 potentially eligible studies were identified, but 7 were duplicates and 67 were excluded after screening the titles and abstracts. Further screening of the full-texts of the remaining 33 articles resulted in the exclusion of 21 studies. Finally, 12 studies were included[8–11,14,15,19–24]. The characteristics of the included studies are summarized in Table 1. Twelve studies (2 RCTs and 10 prospective or retrospective cohort studies) including a total of 30,823 patients were included in our analysis. Of them, 6134 patients were in the TT group and 24,689 patients were in the DT group. The mean follow-up times were between 6 months and 3.3 years and the mean ages were from 65 to 77.5 years. Six studies were monocentric trials and 6 studies were multicenter trials. Most of the patients in our analysis had CHADS2 scores ≥2 and all patients in the TT groups were receiving a combination of warfarin, aspirin, and clopidogrel. The DT group patients were receiving a combination of warfarin and a single antiplatelet drug (mainly aspirin or clopidogrel). Three studies reported short-term follow-up outcomes and 9 studies reported long-term follow-up outcomes. The quality assessment of these studies showed that 1 study[8] had a high risk of bias, but the remaining studies had low risks of bias (see Table 1).

3.2. Major adverse cardiovascular events

There were no detectable differences in MACE between the TT and DT regimens (\( RR = 0.82, 95\% \) CI: 0.58–1.17; \( P = 87.3\% \)). High heterogeneity was identified between the studies (Fig. 2) and similar results were observed in the 2 subgroups. The funnel plot showed obvious asymmetry in Egger test (\( P = .02 \)), but the sensitivity analysis did not find an impact of any individual trials on the MACE results.

3.3. Stroke

No significant differences were found in stroke between the TT and DT regimens (\( RR = 1.08, 95\% \) CI: 0.56–2.07), with significant heterogeneity between the studies (\( I^2 = 65.5\%, P = .002 \)). Similar results were observed in the 2 subgroups (Fig. 3). The funnel plot did not show asymmetry in Egger test (\( P = .184 \)).

3.4. Myocardial infarction

The results of our analysis showed that TT elicited a greater reduction in MI than in the DT regimen (\( RR = 0.59, 95\% \) CI: 0.50–0.70), without significant heterogeneity between the trials (\( I^2 = 31.1\% , P = .169 \)). A similar finding was observed in the long-term follow-up group (\( RR = 0.60, 95\% \) CI: 0.51–0.71), but no significant difference was found in the short-term follow-up group (\( RR = 0.47, 95\% \) CI: 0.21–1.07). The data are presented in
Fig. 4. The funnel plot did not show asymmetry in Egger test ($P = .293$).

3.5. All-cause mortality

No significant differences were found in all-cause mortality between the TT and DT regimens (RR = 0.90, 95% CI: 0.54–1.51; $I^2 = 79.1\%$), with significant heterogeneity between the studies (Fig. 5). Similar findings were observed in the subgroup analyses. The funnel plot showed obvious asymmetry in Egger test ($P = .002$), but the sensitivity analysis did not find an impact of any individual trial on the mortality result.

3.6. Major bleeding

A significantly decreased risk of major bleeding was found between the TT and DT regimens (RR = 0.86, 95% CI: 0.74–0.99; Fig. 6), but significant heterogeneity was not found ($I^2 = 24.3\%$, $P = .205$).

### Table 1

Baseline characteristics of the included studies.

| Study            | Year   | Study design | Sample size | Country   | Mean age, y | CHADS2 score $\geq 2$ (TT/DT)% | TT          | DT          | Mean follow-up | Risk of bias |
|------------------|--------|--------------|-------------|-----------|-------------|--------------------------------|-------------|-------------|----------------|--------------|
| WOEST 2013       | RCT    | 581          | Multicenter | 70.3      | 88/88       | OAC+A+C                        | OAC+C       | 1 y         | Low            |              |
| ISAR-TRIPLE 2015 | RCT    | 614          | Multicenter | 73.6      | 78.9/83.4   | OAC+A+C                        | OAC+C       | 9 mo        | Low            |              |
| Lamberts et al[19] 2013 | Retrospective cohort study | 3948 | Denmark | 71.3 | 90.1/90.7 | OAC+A+C                        | OAC+A; OAC+C | 1 y         | Low            |              |
| Rubboli et al[21] 2014 | Prospective Cohort study | 752 | Multicenter | 73.5 | 71/77       | OAC+A+C                        | OAC+C       | 1 year       | Low            |              |
| Gao et al[9] 2010 | Prospective Cohort study | 257 | China | 71.8 | 49.6/60.9 | OAC+A+C                        | OAC+A; OAC+C | 1 year       | Low            |              |
| Nguyen et al[3] 2007 | Retrospective cohort study | 800 | Multicenter | 65 | NR         | OAC+A+C                        | OAC+A; OAC+C | 6 mo        | Low            |              |
| Sambola et al[9] 2009 | Prospective Cohort study | 324 | Multicenter | 71 | 66.2/58.7 | OAC+A+C                        | OAC+A; OAC+C | 6 mo        | Low            |              |
| Persson et al[22] 2011 | Prospective Cohort study | 605 | Sweden | 68 | NR         | OAC+A+C                        | OAC+C       | 1 y         | Low            |              |
| Claudio et al 2016 | Retrospective cohort study | 79 | Italy | 73 | NR         | OAC+A+C                        | OAC+A; OAC+C | 378 d       | Low            |              |
| Renato et al 2016 | Prospective Cohort study | 1623 | Multicenter | 77.5 | NR         | OAC+A+C                        | OAC+A; OAC+C | 2 y         | Low            |              |
| Karjalainen et al 2007 | Retrospective cohort study | 151 | Finland | 70 | NR         | OAC+A+C                        | OAC+C       | 1 y         | Low            |              |
| Hansen et al[23] 2010 | Retrospective cohort study | 21036 | Denmark | 70 | NR         | OAC+A+C                        | OAC+A; OAC+C | 3.3 y       | Low            |              |

$A =$ aspirin, $MA =$ any antiplatelet, $C =$ clopidogrel, $DT =$ dual therapy, $OAC =$ oral anticoagulant, $RCT =$ randomized controlled trials, $TT =$ triple therapy.
Figure 2. Forest plot of MACE. CI = confidence intervals, DT = dual therapy, MACE = major adverse cardiovascular events, RR = relative risk, TT = triple therapy.

Figure 3. Forest plot of stroke. CI = confidence intervals, DT = dual therapy, RR = relative risk, TT = triple therapy.
Figure 4. Forest plot of MI. CI = confidence intervals, DT = dual therapy, MI = myocardial infarction, RR = relative risk, TT = triple therapy.

Figure 5. Forest plot of all-cause mortality. CI = confidence, DT = dual therapy, RR = relative risk, TT = triple therapy.
A similar finding was observed in the long-term follow-up group (RR = 0.85, 95% CI: 0.73–0.99), but no significant difference was found in the short-term follow-up group (RR = 0.96, 95% CI: 0.60–1.52). The funnel plot showed obvious asymmetry in Egger test ($P = .025$), but the sensitivity analysis did not find an influence of any individual trial on the result of major bleeding.

3.7. Stent thrombosis

The risk of stent thrombosis was not significantly different between the TT and DT regimens (RR = 0.71, 95% CI: 0.41–1.24; $I^2 = 12.7\%$, $P = .333$), without significant heterogeneity between the trials (Fig. 7). Similar findings were observed in the 2 subgroup analyses. The funnel plot did not show asymmetry in Egger test ($P = .619$).

3.8. TT versus OAC and clopidogrel

We also compared TT with OAC and clopidogrel in terms of MACE, stroke, MI, all-cause mortality, major bleeding, and stent thrombosis. No significant differences were found (see Figure A-F, Supplemental Content, http://links.lww.com/MD/B862), but significant heterogeneity was found for MACE and all-cause mortality ($I^2 = 73.6\%$, $P = .004$; and $I^2 = 63.9\%$, $P = .040$; respectively). After removing the source of heterogeneity (WOEST investigators), this heterogeneity was reduced to $I^2 = 53.7\%$ and $I^2 = 28.4\%$, in the MACE group and all-cause mortality group, respectively.

4. Discussion

The main results of the present meta-analysis were that no significant differences were found in the rates of MACE, all-cause mortality, stroke, or stent thrombosis between the TT and DT regimens, but significantly lower risks of MI and major bleeding were identified with TT. Furthermore, the results of the comparison of TT with OAC and clopidogrel showed that OAC and clopidogrel treatment had similar efficacy and safety outcomes compared with TT.

The optimal antithrombotic regimen for patients on long-term oral anticoagulants undergoing coronary stent implantation remains controversial. There is enough evidence to demonstrate that OAC is necessary for AF patients. In general, compared with placebo, OAC can reduce the risk of stroke and systemic embolism by approximately 60% and by approximately 40% compared with aspirin. The current guidelines recommend that DAPT is the standard treatment for patients undergoing coronary stenting or for those experiencing ACS. DAPT is less effective in stent prevention compared with OAC and OAC are less effective in stent thrombosis prevention than DAPT. Therefore, TT has been used as the optimal antithrombotic treatment in patients who are on OAC and require PCI. Indeed, TT is associated with a lower risk of cardiovascular events, but at the cost of an increased risk of major bleeding. This conclusion has been confirmed by previous meta-analyses.

The reduction in ischemic stroke with TT was balanced by the reduction in bleeding with DAPT. More and more studies consider that TT cannot be used as a standard treatment for patients with indications for OAC who have undergone PCI with stent implantation. Therefore, many studies have assessed the benefits and risks of DT compared with TT, but the results have been inconsistent. The WOEST (What Is the Optimal Antiplatelet and Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary Stenting) trials, which represented the first open-label, randomized, multicenter study, demonstrated that OAC with clopidogrel treatment was associated with a significantly lower rate of bleeding, without increasing the rate of thrombotic events. Moreover, the prospective observational AFCAS trial and the large nationwide Danish registry confirmed that OAC with clopidogrel treatment was similar or better in terms of both efficacy and safety outcomes than TT in real-world populations.
However, our study was different from several previous meta-
analyses relative to the comparison of TT with OAC and a single 
antiplatelet.[6,12,13,31] Compared with other meta-analyses, our 
study had apparent advantages. First, the present meta-analysis 
included 12 studies with a total of 30,823 patients, representing 
far more subjects than these previous meta-analyses. Second, 
these recently published meta-analyses had data selection biases, 
such as the inclusion of the data on OAC with clopidogrel alone 
even though the included studies provided data on both OAC and 
aspirin and OAC with clopidogrel, respectively,[13] leading to 
results that indicated that TT showed a greater reduction in major 
bleeding than the DT regimen. Furthermore, after eliminating 2 
studies (Lamberts et al[19] and Hansen et al[24]), no signifi-
cant differences were found in major bleeding between the TT and DT 
regimens. We think that the main reason for this phenomenon is 
that the weight of the 2 studies is too large.

The studies included in our analysis did not report interna-
tional normalized ratio (INR) values. In fact, warfarin with a 
lower INR (1.6–2.5) combined with DAPT has a similar bleeding 
risk compared with DAPT.[32,33] In our study, only 6 studies 
assessed the risk of stroke with CHADS2 scores and 2 studies 
assessed the risk of bleeding with HAS-BLED scores, but we 
know that detailed risk stratification should be carried out to 
balance the risks of stroke and bleeding before initiating 
antithrombotic therapy. Finally, we did not analyze the effect of 
newer P2Y12 inhibitors (prasugrel or ticagrelor), which are 
associated with more obvious platelet inhibition and higher 
bleeding rates than clopidogrel.[34,35] Furthermore, novel oral 
anticoagulants have demonstrated their superiority over warfarin 
in AF patients.[36–38] These drugs may be the best replacements 
for warfarin and could improve the risk/benefit ratio. A recent 
study showed that among participants with atrial fibrillation who 
underwent PCI with stenting, the administration of either 
rivaroxaban along with a P2Y12 inhibitor or rivaroxaban along 
with DAPT was associated with a lower rate of clinically 
significant bleeding than standard therapy with a vitamin K 
antagonist plus DAPT,[39] but a high INR (2.0–3.0) may limit this 
power.

Our study has some limitations. First, the present meta-analysis 
could not obtain individual data. Second, although the results of 
our study were robust, a publication bias was identified. 
Therefore, we should interpret the results carefully and more 
well-designed studies are needed. Third, different studies with 
different inclusion criteria, different designs and clinical 
characteristics, and different endpoint definitions, leading to 
significant heterogeneity, were included in our article. Fourth, 
although these data suggest that the TT may reduce the incidence 
of MI, the result is heavily dependent on 1 study (Lamberts 
et al[19]). Finally, most studies were from western countries, with 
only 1 study from Asian countries, so we cannot conclude on 
whether the results of our article apply to Asian populations.

5. Conclusion

In patients on OAC undergoing PCI with stent implantation, TT 
shows equal effectiveness in terms of MACE, stroke, all-cause 
mortality, and stent thrombosis and lower risks of MI and major 
bleeding than does DT. However, compared with OAC and 
clopidogrel treatment, TT was associated with similar efficacy 
and safety outcomes.
References

[1] Butchart EG, Gohlike-Barwolf C, Antunes MJ, et al. Recommendations for the management of patients after heart valve surgery. Eur Heart J 2005;26:2463–71.

[2] King SBIII, Smith SC Jr, Jacobs AK, et al. ACC/AHA/S�SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol 2008;51:172–209.

[3] Lip GY, Huber K, Andreotti F, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost 2010;103:13–28.

[4] De Eugenio D, Kolman L, DeCaro M, et al. Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy. Pharmacotherapy 2007;27:691–6.

[5] Khurram Z, Chou E, Minutello R, et al. Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding. J Invasive Cardiol 2006;18:162–4.

[6] Cao Y, Tian XY, Zhang R, et al. Short- and long-term efficacy and safety of triple vs. dual antithrombotic therapy in patients with drug-eluting stent implantation and an indication for oral anticoagulation: a meta-analysis. Int J Clin Pharmacol Ther 2016;54:950–65.

[7] Liu J, Fan MD, Zhao JJ, et al. Efficacy and safety of antithrombotic regimens after coronary intervention in patients on oral anticoagulation: traditional and Bayesian meta-analysis of clinical trials. Int J Cardiol 2016;205:89–96.

[8] Gao F, Zhou YJ, Wang ZJ, et al. Comparison of different antithrombotic regimens for patients with atrial fibrillation undergoing drug-eluting stent implantation. Circ J 2010;74:701–8.

[9] Fiedler KA, Maeng M, Mehli J, et al. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE Trial. J Am Coll Cardiol 2015;66:1619–29.

[10] Sambola A, Ferreira-Gonzalez I, Angel J, et al. Therapeutic strategies after coronary stenting in chronically anti-coagulated patients: the MUSICA study. Heart 2009;95:1483–8.

[11] Dewilde WJ, Orbans T, Verheugt FW, et al. WOEST study investigators’ use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013;381:1107–15.

[12] Barbieri L, Verdoia M, Schaffer A, et al. Risk and benefits of triple therapy in patients undergoing coronary stent implantation requiring oral anticoagulation: a meta-analysis of 16 studies. Cardiovasc Drugs Ther 2016;30:61–22.

[13] Briassoulis A, Papageorgiou N, Zacharia E, et al. Meta-analysis of oral anticoagulants with dual versus single antiplatelet therapy in patients after percutaneous coronary intervention. Am J Cardiovasc Drugs 2016;16:103–10.

[14] De Vecchis R, Cantatrione C, Mazzei D. Clinical relevance of anticoagulation and dual antiplatelet therapy to the outcomes of patients with atrial fibrillation and recent percutaneous coronary intervention with stent. J Clin Med Res 2016;8:153–61.

[15] Lopes RD, Rao M, Simon DN, et al. Triple vs dual antithrombotic therapy in patients with atrial fibrillation and coronary artery disease. Am J Med 2016;129:592–9.

[16] Moher D, Liberati A, Tetzlaff J. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264–9.

[17] Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.

[18] Deeks JJ, Altman DG, Bradburn MJ, Egger M, Smith GD, Altman DG. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. Systematic Reviews in Health Care: Meta-Analysis in Context 2nd ed. BMJ Publishing Group, London 2003;285:312–3.

[19] Lamberts M, Goliason GH, Olesen JB, et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol 2013;62:981–9.

[20] Nguyen MC, Lim YL. GRACE Investigators. Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Triple Antithrombotic Therapy and PCI Coronary Events: is it safe and effective to use just one antiplatelet agent? Eur Heart J 2007;28:1717–22.

[21] Rubboli A, Schlitt A, Kivimäki T, et al. AFCAS Study Group. One-year outcome of patients with atrial fibrillation undergoing coronary artery stenting: an analysis of the AFCAS registry. Clin Cardiol 2014;37:357–64.

[22] Persson J, Lindbäck J, Hofman-Bang C, et al. Efficacy and safety of clopidogrel with PCI with stenting on patients on oral anticoagulants with acute coronary syndrome. EuroIntervention 2011;6:1946–52.

[23] Karjalainen PP, Porera P, Ylitalo A, et al. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J 2007;28:726–32.

[24] Hansen ML, Sørensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010;170:1433–41.

[25] Lip GY, Hart RG, Conway DS. Antithrombotic therapy for atrial fibrillation. BMJ 2002;325:1022–3.

[26] Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857–67.

[27] Januzzi JT, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014;64:e1–76.

[28] Orford JK, Fasseas P, Mulby S, et al. Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. Am Heart J 2004;147:461–7.

[29] Muttukrishna S, Reed PS, Gallagher MJ, et al. Evaluation of safety of warfarin in combination with antiplatelet therapy for patients treated with coronary stents for acute myocardial infarction. J Interv Cardiol 2006;18:163–6.

[30] Gao XF, Chen Y, Fan ZG, et al. Antithrombotic regimens for patients taking oral anticoagulation after coronary intervention: a meta-analysis of 16 clinical trials and 9185 patients. Clin Cardiol 2015;38:499–509.

[31] Chao FC, Bin C, Zhu J, et al. Antithrombotic therapy after percutaneous coronary intervention in patients requiring oral anticoagulant treatment: a meta-analysis. Herz 2015;40:1070–83.

[32] Rossini R, Musumeci G, Lettieri C, et al. Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. Am J Cardiol 2008;102:1618–26.

[33] Konishi H, Miyauchi K, Kasai T, et al. Adequate time in therapeutic INR range using triple antithrombotic therapy is not associated with long-term cardiovascular events and major bleeding complications after drug-eluting stent implantation. J Cardiol 2016;68:517–22.

[34] Hamman CW, Bassand JP, Agewali S, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST segment elevation of the European Society of Cardiology (ESC). G Ital Cardiol 2012;13:171–228.

[35] Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045–57.

[36] Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation undergoing coronary artery stenting. N Engl J Med 2009;361:928–38.

[37] Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981–92.

[38] Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883–91.